4 Topic Commentaries

Psilocybin services face real-world test

• 

  Todd Korthuis, MD, MPH

  Addiction Medicine; General Internal Medicine and Geriatrics

  •

  Oregon Health & Science University

  “Safety was very similar to what we’ve seen with psychedelics in clinical settings,” “That’s important because there was a big question around whether or not safety in carefully controlled psilocybin clinical trials would translate into real-world use.”

  Source
• 

  Adrianne R. Wilson-Poe, PhD

  Neuroscience

  •

  Legacy Research Institute

  “This paper is going to be cited for decades,” “This is the first large-scale study to monitor the safety and mental health symptoms of real people in the real world.”

  Source
• 

  Albert Garcia-Romeu, PhD

  Psychiatry and Behavioral Sciences; Psychopharmacology

  •

  Johns Hopkins University School of Medicine

  “If people are taking this at home, at a festival or in some other setting, it’s really difficult to predict what would happen in terms of mental health,” “So now, we have a more well-informed picture of what it looks like when people are using psilocybin ‘in the wild.’”

  Source
• 

  Sandeep Nayak, MD

  Psychiatry

  •

  Johns Hopkins University School of Medicine

  “Clinical trial participants are sometimes having 25 hours of contact with a psychotherapist, so that’s not necessarily comparable” to taking psilocybin outside of a study, “Being able to study psychedelics, not just in the lab, but also outside of it, really does help to start to pin down what is the drug effect and what is the product of mutable contextual changes.”

  Source